Rangeley Capital’s Standard BioTools LAB Stock Holding History

Rangeley Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$46K	–	198
2026 Q1	$46K	Buy	+50,000	New	+$60.5K	0.04%	132

Other funds holding LAB

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Rangeley Capital's LAB Position: Q2 2026 in Review

Rangeley Capital sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 50,000 shares — an estimated $46K sold.

Rangeley Capital first reported a position in LAB in Q1 2026 and held it in 1 quarter. The position peaked at $46K in Q1 2026. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

Rangeley Capital reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
Rangeley Capital sold 50,000 Standard BioTools shares in Q2 2026, an estimated $46K.
Rangeley Capital first reported a position in Standard BioTools in Q1 2026 and held it in 1 quarter.
Rangeley Capital's Standard BioTools position peaked at $46K in Q1 2026.
143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.